<DOC>
	<DOCNO>NCT01859728</DOCNO>
	<brief_summary>To evaluate safety efficacy combination cisplatin plus irinotecan treatment biliary tract cancer .</brief_summary>
	<brief_title>GAMBIT Trial : Cisplatin Plus Irinotecan Treatment Gallbladder Biliary Tract Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<criteria>biopsyproven gallbladder biliary tract cancer ; Recurrent , metastatic unresectable disease ; Chemona√Øve . Not candidate curativeintent treatment , surgery radiationtherapy ; Measurable disease accord RECIST 1.1 ; ECOG 02 ; Adequate hematologic biochemistry test ; Creatinine clearance &gt; = 60ml/min . Known hypersensibility previous therapy cisplatin , gemcitabine irinotecan ; Chronic immunosuppressive therapy ; Known CNS metastasis ; Previous diagnosis cancer ; Chronic acute active infection , except asymptomatic HIV infection ; Active bleeding ; Any severe medical condition ; Pregnant lactate woman , childbearing potential ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>biliary cancer</keyword>
	<keyword>irinotecan</keyword>
	<keyword>cisplatin</keyword>
	<keyword>gemcitabine</keyword>
</DOC>